Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14516273 | 0.82 | PDE4A (0.36) | ADORA2B | |
| SCHEMBL13483449 | 0.78 | TLR8 (0.42) | ADORA2BMAPT | |
| SCHEMBL10072552 | 0.78 | GSK3A (0.34) | ADORA2BMAPT | |
| SCHEMBL25045667 | 0.76 | BRD4 (0.36) | ADORA2B | |
| SCHEMBL26454678 | 0.76 | — | — | |
| SCHEMBL12128675 | 0.73 | ADORA2B (0.31) | ADORA2B | |
| SCHEMBL14600369 | 0.73 | KMT2A (0.45) | ADORA2BMAPT | |
| SCHEMBL6736338 | 0.70 | LPO (0.32) | ADORA2B | |
| SCHEMBL6778160 | 0.68 | MAPK8 (0.37) | — | |
| SCHEMBL25593649 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635706-B2 | 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| EP-1638959-B1 | 5HT -4 -ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2007-09-19 | — | — | EP | disclosed |
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-6800628-B2 | SUCH AS (1-(2-((3-METHYL-2-PYRAZINYL)AMINO)ETHYL)-4-PIPERIDINYL)-METHYL-4-AMINO-5 -CHLORO-2,3-DIHYDRO-7-BENZOFURANCARBOXYLATE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-05 | — | — | US | disclosed |
| US-20030153573-A1 | Novel N-substituted 4-((-4'-aminobenzoyl)-oxymethyl)-piperidines having gastric prokinetic properties | BOSMANS JEAN-PAUL RENE MARIE (BE) | 2003-08-14 | — | — | US | disclosed |
| EP-0885190-B1 | N-SUBSTITUTED 4-((4'-AMINOBENZOYL)-OXYMETHYL)-PIPERIDINES HAVING GASTRIC PROKINETIC PROPERTIES | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-07 | — | — | EP | disclosed |
| US-6509339-B2 | Gastrointestinal disorders; cardiovascular disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-21 | — | — | US | disclosed |
| US-20020042430-A1 | Novel esters of 1, 4-disubstituted piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE (BE) | 2002-04-11 | — | — | US | disclosed |
| US-6291481-B1 | CONDITIONS RELATED TO A HAMPERED OR IMPAIRED GASTRIC EMPTYING AND MORE GENERALLY TO TREAT CONDITIONS RELATED TO A HAMPERED OR IMPAIRED GASTROINTESTINAL TRANSIT. | JANSSEN PHARMACEUTICA, N.V. (BE) | 2001-09-18 | — | — | US | disclosed |
| EP-0885190-A1 | NOVEL N-SUBSTITUTED 4-((4'-AMINOBENZOYL)-OXYMETHYL)-PIPERIDINES HAVING GASTRIC PROKINETIC PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997031897-A1 | NOVEL N-SUBSTITUTED 4-((4'-AMINOBENZOYL)-OXYMETHYL)-PIPERIDINES HAVING GASTRIC PROKINETIC PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042430-A1 | Novel esters of 1, 4-disubstituted piperidine derivatives | CBR1, ALK, ESRRA | ADORA2B 542/4885MAPT 4859/4885 |
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | HTR4, HTR2B, TPH2 | ADORA2B 57/4885MAPT 3488/4885 |
| US-20030153573-A1 | Novel N-substituted 4-((-4'-aminobenzoyl)-oxymethyl)-piperidines having gastric prokinetic properties | GIPR, CRHR1, GRPR | ADORA2B 261/4885MAPT 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.